查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008352

神經科學市場：依產品類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

Neuroscience Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，神經科學市場價值將達到 167.7 億美元，到 2026 年將成長到 186.1 億美元，到 2032 年將達到 341.5 億美元，複合年成長率為 10.69%。

主要市場統計數據
基準年 2025 167.7億美元
預計年份：2026年 186.1億美元
預測年份 2032 341.5億美元
複合年成長率 (%) 10.69%

對當前神經科學趨勢的簡要概述，抓住塑造技術創新、相關人員合作和臨床應用的策略轉折點。

神經科學生態系統正處於快速技術創新和臨床範式轉變的交匯點，促使產業界、學術界和醫療服務機構的領導者重新評估優先事項和投資策略。影像解析度、訊號處理和演算法解讀的進步使得更精準的診斷和更精細的治療性介入成為可能，而工程師、臨床醫生和資料科學家之間日益密切的跨學科合作也加速了轉化研究的進程。同時，醫療系統正努力應對不斷變化的報銷機制和日益成長的基於價值的治療結果期望，尤其關注可驗證的臨床效用和成本效益。

詳細概述了推動神經科學研究和臨床實踐模式轉移的技術、監管和商業的融合力量。

在技​​術成熟、監管演變和相關人員期望轉變這三大相互關聯的趨勢的驅動下，一場突破性的變革正在進行，它正在重新定義神經科學領域的競爭格局和臨床實踐。在技​​術層面，高解析度磁振造影和先進的腦電圖平台等技術的進步提高了診斷準確性，並促進了新生物標記的發現。同時，從先進的分析流程到視覺化套件，軟體的同步改進正在加速從發現到臨床決策的進程，將原始數據轉化為可操作的洞見。

對 2025 年關稅調整將如何重塑神經科學技術提供者的供應鏈策略、採購選擇和業務永續營運進行全面分析。

2025年實施的關稅和貿易調整措施，為支持神經科學技術的供應鏈增添了新的複雜性，對採購、製造和服務交付等各個環節都產生了累積影響。進口零件和成品關稅的提高，促使許多供應商重新評估其供應商所在地，並考慮採取地域多元化策略，以保護自身業務免受貿易波動的影響。實際上，採購團隊面臨著不斷上漲的到貨成本和更長的前置作業時間，這要求他們在庫存管理和合約條款方面進行策略性調整，以確保向臨床客戶和研究合作夥伴持續供應產品。

將產品層級、模式技術、臨床應用和買家類型連結起來的多維細分框架，能夠制定針對每個產業的商業化策略。

細分市場分析揭示了產品、技術、應用和最終用戶這四個類別各自需要不同的策略和專業化的服務。依產品類型，市場可分為「設備」、「服務」及「軟體」三大類。其中，設備包括「影像設備」、「監測設備」和「治療設備」。影像設備涵蓋多種模式，例如電腦斷層掃描 (CT) 掃描儀、腦電圖 (EEG) 掃描儀和磁振造影(MRI) 掃描儀，每種模式都需要不同的開發藍圖和臨床檢驗流程。監測設備分為侵入性監測設備和非侵入性監測設備，每種設備都有不同的監管要求和臨床實施考量。治療設備包括神經調控設備和復健設備，這些設備需要強力的證據證明其具有持續的治療效果，並需要明確的患者選擇標準。服務進一步細分為諮詢服務和維護服務，體現了諮詢能力在臨床實施和售後支援中的重要性。軟體包括分析軟體和視覺化軟體，互通性、監管分類和使用者體驗是實施的關鍵因素。

對美洲、歐洲、中東和非洲以及亞太地區的採用趨勢、監管環境和商業化重點進行戰略區域展望。

區域趨勢對策略重點、監管方式和臨床部署速度有顯著影響。在美洲，創新中心和成熟的臨床研究網路正在推動先進成像和監測設備的早期應用。同時，健保報銷機制和大規模綜合醫療服務網路正在影響採購計劃和對成熟價值的需求。臨床試驗活動以及與製藥研發公司的合作也催生了對研究設備和分析平台的需求。

這項企業級分析重點闡述了硬體、軟體和服務的整合，以及證據和互通性如何推動競爭差異化。

企業層面的關鍵洞察揭示了一個日益由差異化驅動的競爭格局，這種差異化體現在整合解決方案、證據產生和卓越的售後服務上。領先的醫療設備製造商正在投資高解析度硬體和模組化平台，以支援多模態成像和高效的升級路徑，從而建立長期的客戶關係並減少整個生命週期中的摩擦。同時，專業軟體公司正透過提供先進的分析引擎和以使用者為中心的視覺化工具來擴大其影響力，這些工具可以縮短解讀時間並提高診斷信心。

為領導者提供具體可行的策略和營運建議，以加速臨床應用、增強韌性、產生證據並加強綜合經營模式。

產業領導者應推動一系列切實可行的舉措，將洞察轉化為營運優勢。首先，他們需要對產品組合進行策略性優先排序，使產品開發資源與具有高影響力的臨床應用以及支援這些應用的監管路徑相符。優先事項應包括增強資料互通性、投資於能夠證明實際應用效益的可靠檢驗研究，以及設計將醫療設備、分析和服務整合在一起的靈活商業模式。這將有助於各機構減少臨床實踐中的摩擦，並更好地滿足支付方和醫療服務提供者的期望。

採用透明、多方面的研究途徑，結合專家訪談、文獻整合和情境分析，檢驗研究結果，並支持可操作的結論。

本分析的調查方法結合了定性和定量方法，以確保研究的嚴謹性和有效性。主要調查包括對臨床醫生、監管專家、採購經理和研發主管等領域專家進行結構化訪談，以收集第一線專家的觀點。次要調查包括對同行評審文獻、監管指導文件、臨床試驗註冊資訊和公開文件進行系統性回顧，以全面檢驗研究結果並確定特定技術方面的考慮因素，例如治療模式的性能和實施要求。

這項具有前瞻性的綜合分析概述了技術的整合、檢驗和穩健實施如何決定神經科學領域的競爭優勢和臨床影響。

總之，在技術進步、法規結構轉變和不斷變化的商業性預期等因素的驅動下，神經科學領域正進入一個加速轉型期。醫療設備創新、先進軟體功能和增強服務模式的相互作用，正為更早的診斷、更精準的監測和更有效的治療方法鋪平道路。儘管供應鏈調整和區域監管趨勢日益複雜，但也為透過在地化生產、卓越的服務網路和針對性證據的創建實現策略差異化提供了機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：神經科學市場：依產品類型分類

  • 醫療設備
    • 醫療影像設備
      • 電腦斷層掃描器
      • 腦電圖（EEG）測量設備
      • 磁振造影系統
    • 監控設備
      • 侵入式監測設備
      • 非侵入式監測設備
    • 治療設備
      • 神經控制裝置
      • 復健設備
  • 服務
    • 諮詢服務
    • 維護服務
  • 軟體
    • 分析軟體
    • 視覺化軟體

第9章：神經科學市場：依技術分類

  • 電腦斷層掃描
  • 腦電圖（EEG）
  • 功能性近紅外線光譜
  • 磁振造影
  • 腦磁圖

第10章：神經科學市場：依應用領域分類

  • 診斷
    • 心血管疾病
    • 神經系統疾病
    • 腫瘤影像
  • 監測
  • 調查
  • 治療
    • 神經調控
    • 復健治療

第11章 神經科學市場：依最終用戶分類

  • 診所
  • 醫院
  • 製藥公司
  • 研究機構

第12章 神經科學市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：神經科學市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 神經科學市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國神經科學市場

第16章：中國神經科學市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Blackrock Neurotech
  • DeepMind Technologies
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • NeuroPace
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-C002B1C9955F

The Neuroscience Market was valued at USD 16.77 billion in 2025 and is projected to grow to USD 18.61 billion in 2026, with a CAGR of 10.69%, reaching USD 34.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.77 billion
Estimated Year [2026] USD 18.61 billion
Forecast Year [2032] USD 34.15 billion
CAGR (%) 10.69%

A concise overview of the current neuroscience landscape capturing technological innovation, stakeholder convergence, and the strategic inflection points shaping clinical adoption

The neuroscience ecosystem stands at the intersection of rapid technological innovation and shifting clinical paradigms, prompting leaders across industry, academia, and healthcare delivery to reassess priorities and investment theses. Advances in imaging resolution, signal processing, and algorithmic interpretation are enabling more precise diagnostics and refined therapeutic interventions, while growing interdisciplinary collaboration between engineers, clinicians, and data scientists accelerates translational progress. Concurrently, health systems are contending with evolving reimbursement frameworks and heightened expectations for value-based outcomes, which places a premium on demonstrable clinical utility and cost-effectiveness.

Throughout this report, we emphasize the convergence of device innovation, software sophistication, and service models that together reshape how neurological conditions are detected, monitored, and treated. The introductory analysis synthesizes key drivers such as regulatory pathways that incentivize safety and performance, advances in analytics that unlock latent clinical signals, and operational demands that require scalable maintenance and consultancy support. By clarifying these forces, readers will gain a cohesive understanding of the current landscape and the strategic inflection points that will determine competitive advantage in the near to medium term.

An in-depth synthesis of converging technological, regulatory, and commercial forces that are driving paradigm shifts across neuroscience research and clinical practice

Significant transformative shifts are redefining competitive dynamics and clinical practice within neuroscience, driven by three interrelated currents: technological maturation, regulatory evolution, and shifting stakeholder expectations. On the technology front, enhancements in modalities such as high-resolution magnetic resonance techniques and advanced electroencephalography platforms are expanding diagnostic clarity and enabling novel biomarkers. Parallel improvements in software, from advanced analysis pipelines to visualization suites, are converting raw data into actionable insights, thereby accelerating the path from discovery to clinical decision-making.

Regulatory frameworks are evolving to accommodate software as a medical device and hybrid hardware-software systems, which incentivizes rigorous validation and post-market surveillance while creating clearer pathways for safer deployment. Simultaneously, purchasers and care providers are prioritizing real-world evidence and demonstrable outcomes, driving vendors to integrate services such as consultancy and maintenance into their value propositions. As a result, business models are shifting from product-centric sales to outcome-oriented solutions, with bundled offerings that combine devices, analysis software, and ongoing support gaining traction. These shifts are spurring new partnerships across device manufacturers, clinical research organizations, and analytics firms, ultimately accelerating adoption in clinical and research settings.

A comprehensive analysis of how 2025 tariff adjustments have reshaped supply chain strategies, sourcing choices, and operational resilience across neuroscience technology providers

The imposition of tariffs and trade adjustments in 2025 introduced a layer of complexity for supply chains that underpin neuroscience technologies, with cumulative impacts felt across sourcing, manufacturing, and service delivery. Increased duties on imported components and finished goods have led many suppliers to reassess supplier footprints and to consider regional diversification strategies to insulate operations from trade volatility. In practice, procurement teams face higher landed costs and longer lead times, prompting strategic shifts in inventory management and contractual terms to preserve continuity for clinical customers and research partners.

In response, several manufacturers have accelerated nearshoring and re-shoring initiatives, moving certain assembly and calibration activities closer to primary end markets to mitigate tariff exposure and reduce transit-related disruption. These changes have required capital investment and operational retooling, as well as renewed focus on supplier qualification and local regulatory compliance. Moreover, service providers that rely on cross-border technician mobility and spare-part exchanges have had to adapt service models, investing in local technician training and regional parts depots to maintain responsiveness. Taken together, these adaptations highlight the need for flexible supply chain strategies that balance cost, compliance, and uptime in the face of evolving trade policy.

A multidimensional segmentation framework linking product hierarchies, modality technologies, clinical applications, and purchaser types to inform tailored commercialization strategies

Segmentation analysis illuminates how distinct product, technology, application, and end-user categories demand tailored strategies and specialized offerings. Based on Product Type, the market can be parsed into Devices, Services, and Software, with Devices encompassing Imaging Devices, Monitoring Devices, and Therapeutic Devices. Within Imaging Devices, modalities such as Computed Tomography Devices, Electroencephalography Devices, and Magnetic Resonance Imaging Devices require differentiated development roadmaps and clinical validation pathways. Monitoring Devices break down into Invasive Monitoring Devices and Non Invasive Monitoring Devices, each presenting divergent regulatory requirements and clinical deployment considerations. Therapeutic Devices include Neuromodulation Devices and Rehabilitation Devices, which necessitate strong evidence of sustained outcomes and clear patient selection criteria. Services further subdivide into Consultancy Services and Maintenance Services, reflecting the importance of advisory capabilities and post-sale support for clinical integration. Software comprises Analysis Software and Visualization Software, where interoperability, regulatory classification, and user experience are critical adoption levers.

Based on Technology, offerings span Computed Tomography, Electroencephalography, Functional Near Infrared Spectroscopy, Magnetic Resonance Imaging, and Magnetoencephalography, each technology bringing specific sensitivity profiles, requirements for shielding and environment control, and distinct data management needs. Based on Application, the landscape includes Diagnostics, Monitoring, Research, and Therapy, with Diagnostics further focused on cardiovascular disorders, neurological disorders, and oncology imaging, while Therapy emphasizes neuromodulation and rehabilitation therapy. Each application area imposes unique clinical utility thresholds and evidence requirements, influencing product development and commercialization strategies. Based on End User, primary purchasers include Clinics, Hospitals, Pharmaceutical Companies, and Research Institutes, and each end user type shows different procurement cycles, capital planning horizons, and expectations for integration and service levels. When considered together, these segmentation layers provide a multidimensional framework that supports nuanced go-to-market decisions, prioritization of R&D efforts, and the design of tailored commercial models aimed at accelerating adoption across diverse customer profiles.

Strategic regional perspectives on adoption dynamics, regulatory landscapes, and commercialization priorities across the Americas, Europe Middle East & Africa, and Asia Pacific

Regional dynamics exert a profound influence on strategic priorities, regulatory approaches, and the pace of clinical adoption. In the Americas, innovation hubs and established clinical research networks drive early adoption of advanced imaging and monitoring devices, while reimbursement environments and large integrated delivery networks shape procurement timetables and demand for demonstrated value. Clinical trial activity and collaborations with pharmaceutical developers also create demand for research-grade instrumentation and analytics platforms.

In Europe, the Middle East & Africa, regulatory harmonization efforts and centralized health technology assessment bodies influence the evaluation criteria for new technologies, and heterogeneous reimbursement pathways require customized market access strategies. Additionally, public healthcare systems in several countries prioritize cost-effectiveness and scalability, prompting suppliers to emphasize total cost of ownership and service reliability. The Asia-Pacific region is characterized by rapid infrastructure investment, growing clinical research capacity, and diverse adoption curves across countries. Markets in this region often present opportunities for localized manufacturing, partnerships with academic centers, and tailored training programs to support clinical adoption. Across these regions, strategic considerations include supply chain localization, alignment with regional regulatory expectations, and the development of culturally appropriate training and support materials to ensure successful deployment and sustained use.

Company-level analysis highlighting how integration of hardware, software, and services combined with evidence and interoperability drives competitive differentiation

Key company-level insights reveal a competitive landscape where differentiation is increasingly driven by integrated solutions, evidence generation, and after-sales service excellence. Leading device manufacturers are investing in higher-resolution hardware and modular platforms that support multi-modal imaging and streamlined upgrade paths, enabling long-term customer relationships and reduced lifecycle friction. At the same time, specialized software firms are gaining influence by delivering advanced analysis engines and user-centric visualization tools that reduce interpretation time and enhance diagnostic confidence.

Partnerships between hardware vendors and analytics providers are becoming more commonplace, creating bundled offerings that combine devices, analysis software, and consultancy services to accelerate clinical adoption. Service organizations that can demonstrate rapid deployment capabilities, robust maintenance networks, and regionally accredited training programs are achieving competitive advantage by minimizing downtime and supporting consistent outcomes. Firms that prioritize interoperability, data security, and compliance with evolving regulatory expectations are better positioned to secure large institutional contracts. Collectively, these company-level trends underscore the importance of cross-functional coordination between R&D, regulatory affairs, clinical affairs, and commercial teams to translate technical innovation into sustained market impact.

Actionable strategic and operational recommendations for leaders to strengthen resilience, evidence generation, and integrated commercial models that accelerate clinical adoption

Industry leaders should pursue a set of pragmatic actions to translate insights into operational advantage, beginning with strategic portfolio prioritization that aligns product development resources with high-impact clinical applications and supportive regulatory pathways. Priorities should include strengthening data interoperability, investing in robust validation studies that demonstrate real-world clinical benefit, and designing flexible commercial models that bundle devices, analytics, and services. By doing so, organizations can reduce friction at the point of care and better align with payer and provider expectations.

Operationally, firms should accelerate supply chain resilience initiatives, including diversification of component sourcing, establishment of regional service hubs, and investment in local technician training programs to maintain uptime in the face of trade or logistics disruptions. Commercial teams ought to develop tailored go-to-market approaches for distinct end-user segments, offering differentiated value propositions for clinics, hospitals, pharmaceutical companies, and research institutes. Moreover, forging strategic alliances with early adopter institutions and academic centers can produce the clinical evidence and case studies needed to scale adoption. Finally, leaders should actively monitor regulatory trends and participate in standards-setting forums to shape policy and ensure smoother market entry for integrated hardware-software solutions.

A transparent, multi-method research approach combining expert interviews, literature synthesis, and scenario analysis to validate findings and support actionable conclusions

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure rigor and relevance. Primary research included structured interviews with domain experts encompassing clinicians, regulatory specialists, procurement leaders, and R&D executives to capture on-the-ground perspectives. Secondary research comprised a systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public filings to triangulate findings and verify technology-specific considerations such as modality performance and deployment requirements.

Analytical techniques applied include comparative technology assessments, value-chain mapping, and scenario analysis to evaluate the implications of policy changes and supply chain disruptions. Evidence synthesis prioritized reproducibility and transparency, with clear documentation of data sources, inclusion criteria, and assumptions used in qualitative interpretation. In addition, iterative validation workshops with subject-matter experts were conducted to test preliminary conclusions and enhance the practical applicability of recommendations. Collectively, these methods provide a robust foundation for insights that are both evidence-based and actionable within clinical, research, and commercial contexts.

A forward-looking synthesis outlining how integration of technology, validation, and resilient operations will determine competitive advantage and clinical impact in neuroscience

In conclusion, the neuroscience sector is navigating a period of accelerated transformation driven by technological advances, shifting regulatory frameworks, and evolving commercial expectations. The interplay between device innovation, sophisticated software capabilities, and enhanced service models is creating new pathways for earlier diagnosis, more precise monitoring, and more effective therapies. Supply chain adjustments and regional regulatory dynamics add complexity but also present opportunities for strategic differentiation through localized manufacturing, superior service networks, and targeted evidence generation.

Looking ahead, organizations that prioritize integrated solutions, invest in rigorous clinical validation, and cultivate resilient operational models will be best positioned to capture emerging opportunities. Cross-sector collaboration, informed by transparent data-sharing practices and interoperability standards, will accelerate adoption and improve patient outcomes. By synthesizing the insights presented across these sections, decision-makers can develop focused strategies to navigate uncertainty, align resources with clinical needs, and deliver sustainable value to patients and healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neuroscience Market, by Product Type

  • 8.1. Devices
    • 8.1.1. Imaging Devices
      • 8.1.1.1. Computed Tomography Devices
      • 8.1.1.2. Electroencephalography Devices
      • 8.1.1.3. Magnetic Resonance Imaging Devices
    • 8.1.2. Monitoring Devices
      • 8.1.2.1. Invasive Monitoring Devices
      • 8.1.2.2. Non Invasive Monitoring Devices
    • 8.1.3. Therapeutic Devices
      • 8.1.3.1. Neuromodulation Devices
      • 8.1.3.2. Rehabilitation Devices
  • 8.2. Services
    • 8.2.1. Consultancy Services
    • 8.2.2. Maintenance Services
  • 8.3. Software
    • 8.3.1. Analysis Software
    • 8.3.2. Visualization Software

9. Neuroscience Market, by Technology

  • 9.1. Computed Tomography
  • 9.2. Electroencephalography
  • 9.3. Functional Near Infrared Spectroscopy
  • 9.4. Magnetic Resonance Imaging
  • 9.5. Magnetoencephalography

10. Neuroscience Market, by Application

  • 10.1. Diagnostics
    • 10.1.1. Cardiovascular Disorders
    • 10.1.2. Neurological Disorders
    • 10.1.3. Oncology Imaging
  • 10.2. Monitoring
  • 10.3. Research
  • 10.4. Therapy
    • 10.4.1. Neuromodulation
    • 10.4.2. Rehabilitation Therapy

11. Neuroscience Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Pharmaceutical Companies
  • 11.4. Research Institutes

12. Neuroscience Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neuroscience Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neuroscience Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Neuroscience Market

16. China Neuroscience Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AbbVie Inc.
  • 17.7. Amgen Inc.
  • 17.8. AstraZeneca PLC
  • 17.9. Biogen Inc.
  • 17.10. Blackrock Neurotech
  • 17.11. DeepMind Technologies
  • 17.12. Eli Lilly and Company
  • 17.13. Johnson & Johnson
  • 17.14. Merck & Co., Inc.
  • 17.15. Neurocrine Biosciences, Inc.
  • 17.16. NeuroPace
  • 17.17. Novartis AG
  • 17.18. Pfizer Inc.
  • 17.19. Roche Holding AG
  • 17.20. Sanofi S.A.
  • 17.21. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROSCIENCE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEUROSCIENCE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROSCIENCE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROSCIENCE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEUROSCIENCE MARKET SIZE, BY INVASIVE MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROSCIENCE MARKET SIZE, BY INVASIVE MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEUROSCIENCE MARKET SIZE, BY INVASIVE MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON INVASIVE MONITORING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON INVASIVE MONITORING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON INVASIVE MONITORING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROSCIENCE MARKET SIZE, BY CONSULTANCY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROSCIENCE MARKET SIZE, BY CONSULTANCY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROSCIENCE MARKET SIZE, BY CONSULTANCY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROSCIENCE MARKET SIZE, BY VISUALIZATION SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUROSCIENCE MARKET SIZE, BY VISUALIZATION SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROSCIENCE MARKET SIZE, BY VISUALIZATION SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROSCIENCE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROSCIENCE MARKET SIZE, BY FUNCTIONAL NEAR INFRARED SPECTROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROSCIENCE MARKET SIZE, BY FUNCTIONAL NEAR INFRARED SPECTROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROSCIENCE MARKET SIZE, BY FUNCTIONAL NEAR INFRARED SPECTROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROSCIENCE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROSCIENCE MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROSCIENCE MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROSCIENCE MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROSCIENCE MARKET SIZE, BY ONCOLOGY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUROSCIENCE MARKET SIZE, BY ONCOLOGY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROSCIENCE MARKET SIZE, BY ONCOLOGY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEUROSCIENCE MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROMODULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROSCIENCE MARKET SIZE, BY REHABILITATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROSCIENCE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NEUROSCIENCE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROSCIENCE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROSCIENCE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NEUROSCIENCE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROSCIENCE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS NEUROSCIENCE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL NEUROSCIENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. GCC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 241. GCC NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 242. GCC NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 243. GCC NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 244. GCC NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 245. GCC NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 246. GCC NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. GCC NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. GCC NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 249. GCC NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. GCC NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. G7 NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. G7 NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 280. G7 NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 281. G7 NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 282. G7 NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 283. G7 NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 284. G7 NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 285. G7 NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. G7 NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. G7 NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 288. G7 NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 289. G7 NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. NATO NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. NATO NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. NATO NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 293. NATO NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 294. NATO NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 295. NATO NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 296. NATO NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 297. NATO NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 298. NATO NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. NATO NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. NATO NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 301. NATO NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 302. NATO NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA NEUROSCIENCE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA NEUROSCIENCE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA NEUROSCIENCE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA NEUROSCIENCE MARKET SIZE, BY IMAGING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA NEUROSCIENCE MARKET SIZE, BY MONITORING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA NEUROSCIENCE MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA NEUROSCIENCE MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA NEUROSCIENCE MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA NEUROSCIENCE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA NEUROSCIENCE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA NEUROSCIENCE MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA NEUROSCIENCE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)